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Background: Although the efficacy of prophylactic or therapeutic whole brain radiotherapy (WBRT) for brain
metastases (BM) from small cell lung cancer (SCLC) is well established, the role of stereotactic radiosurgery (SRS) has
yet to be determined. In the present retrospective analysis, we investigated whether upfront SRS might be an
effective treatment option for patients with BM from SCLC.
Methods: We analyzed 41 consecutive patients with a limited number of BM (≤ 10) from SCLC who received SRS
as the initial treatment. No prophylactic and therapeutic WBRT was given prior to SRS. The median patient age was
69 years and the median Karnofsky performance status (KPS) score was 90. Repeat SRS was given for new distant
lesions detected on follow-up neuroradiological imaging, as necessary. Overall survival, neurological death, and local
and distant BM recurrence rates were analyzed. The survival results were tested with three prognostic scoring
systems validated for SCLC: Diagnosis-specific graded prognostic assessment (DS-GPA), Radiation therapy oncology
group -recursive partitioning analysis and Rades’s survival score.
Results: One- and 2-year overall survival rates were 44% and 17%, respectively. The median survival time was
8.1 months. Survival results replicated the DS-GPA (P = 0.022) and Rades’s survival score (P = 0.034). On multivariate
analysis, patients with high KPS (hazard ratio (HR): 0.308, P = 0.009) and post-SRS chemotherapy (HR: 0.324, P = 0.016)
had better overall survival. In total, 95/121 tumors (79%) in 34 patients (83%) with sufficient radiological follow-up
data were evaluated. Six- and 12-month rates of local control failure were 0% and 14%, respectively. Six- and
12-month distant BM rates were 22% and 44%, respectively. Repeat SRS, salvage WBRT and microsurgery were
subsequently required in 18, 7 and one patient, respectively. Symptomatic radiation injury developed in two
patients and both were treated conservatively.
Conclusions: Our survival analyses with the validated prognostic grading systems suggested upfront SRS for
limited BM from SCLC to be a potential treatment option, with patient survival being slightly more than eight
months after SRS. Although SRS provided durable local tumor control, repeat treatment was needed in nearly half
of patients to achieve control of distant BM.
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Table 1 Summary of clinical data from 41 consecutive
patients with BM from SCLC
Characteristics Values
Sex (male/female) 34 / 7
Age (years), median (range) 69 (50–85)
KPS, median (range) 90 (30–100)
Active Extra-CNS disease or Extra-CNS metastasis 25 (61%)
DS-GPA 0–1.0/1.5-2.5/3.0-4.0 20 / 15 / 6
RTOG-RPA class I/class II/class III 6 / 25 / 10
Post-SRS chemotherapy 32 (78%)
Time from primary diagnosis to initial SRS (months),
median (range)
7.8 (0.3-149)
Cumulative PTV on initial SRS (mL), median (range) 3.8 (0.6-28.2)
No. of intracranial lesions on initial SRS,
median (range)
2 (1–10)
BM: brain metastases, SCLC: small cell lung cancer, KPS: Karnofsky
performance status, CNS: central nervous system, DS-GPA: diagnosis-specific
graded prognostic assessment, RTOG-RPA radiation treatment oncology group
recursive partitioning analysis, , SRS: stereotactic radiosurgery, PTV: planning
target volume.
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Small cell lung cancer (SCLC) is the most aggressive
histologic subtype of lung cancer, with a predilection for
early metastases [1]. Brain metastases (BM) are a signifi-
cant threat to quality of life in patients with SCLC [2].
Given that the cumulative incidence of BM from SCLC
at 2 years is approximately 50% [1,3], prophylactic cra-
nial irradiation (PCI) combined with systemic chemo-
therapy, which moderately prolongs overall survival (OS)
by reducing the incidence of delayed BM, has historically
been recommended as the treatment for this aggressive
disease in most patients [4-8].
Stereotactic radiosurgery (SRS) has now emerged as
the preferred treatment modality, either alone or in
combination with other modalities. Recently, in selected
patients, whole brain radiotherapy (WBRT) has been
omitted from the initial management for BM with the
aim of reducing the potential risk of delayed neuro-
logical toxicity [5,9-11]. Given the propensity for dissem-
ination of SCLC, SRS does not appear to be a rational
approach to this pathology. To date, there have been
only a few, relatively small, studies of SRS for SCLC,
which focused mainly on salvage treatment for recur-
rence after WBRT [12-16]. Thus, the role of upfront
focal treatment by means of SRS for BM from SCLC has
yet to be determined. We retrospectively investigated
the efficacy and limitations of an SRS-oriented strategy
for patients with newly diagnosed BM from SCLC.
Methods
Patient population
Between January 2009 and May 2013, 42 patients with
BM originating from histologically proven primary SCLC
underwent Gamma Knife SRS as a part of initial man-
agement. Prior WBRT had not been conducted in either
a prophylactic or a therapeutic setting. All patients in-
cluded in the present study had been diagnosed and
their primary tumors treated at other hospitals, where
the appropriateness of SRS had been determined by the
clinical oncologist and the patient. They were then re-
ferred to our institution to receive SRS for BM. Patients
with up to 10 BM received, in principle, SRS as the ini-
tial therapy. When abnormal enhancement of cranial
nerves, the ventricular ependymal layer and/or the cor-
tical surface or more than 10 BM were documented by
high resolution magnetic resonance (MR) imaging at the
time of initial SRS, WBRT was indicated and such pa-
tients were excluded from the present study. Surgical re-
section was recommended for large tumors with a mass
effect unresponsive to corticosteroid therapy. In the
event of surgery not being feasible due to poor systemic
condition or prognosis, 2-session SRS was conducted for
carefully selected patients with tumors larger than
10 mL [17]. All patients and/or their relatives were fullyinformed that upfront SRS remains an unproven strategy
in terms of safety and efficacy, and all provided written
informed consent. San-ai Hospital Institutional Review
Board approved this retrospective clinical study in Janu-
ary 2014. The current retrospective review involves a
series of 41 consecutive patients who had not more than
10 BM. The one remaining patient receiving upfront
SRS for more than 10 BM, due to refusal to undergo
WBRT, was excluded. Thirty-four patients were male
and 7 were female. The median age was 69 years (range:
50–85). The median Karnofsky performance status
(KPS) score at the time of SRS was 90 (range: 30–100).
The median interval between initial diagnosis and SRS
was 7.8 months (range: 0–149 months). Five patients
had undergone microsurgical resection for large symp-
tomatic BM before SRS. The patient characteristics are
summarized in Table 1.
Radiosurgical indications and techniques
SRS was performed using the Leksell G stereotactic frame
(Elekta Instruments, Stockholm, Sweden). The frame was
placed on the patient’s head under local anesthesia supple-
mented with mild sedation. 3-D volumetric gadolinium-
enhanced T1-weighted magnetic resonance (MR) images,
2 mm in thickness, and T2-weighted MR images and
contrast-enhanced computed tomography covering the
whole brain were routinely used for dose planning with
Leksell Gamma Plan software (Elekta Instruments). Pre-
scribed doses were selected in principle according to the
dose protocol of the JLGK 0901 study [18], though a mar-
gin of approximately 1 to 2 mm was added to the visible le-
sion in consideration of the infiltrative nature of SCLC [19].
The technical details of 2-session SRS were previously
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the Leksell Gamma Knife Model C or Perfexion.
Post-SRS management and follow-up evaluation
Clinical follow-up data as well as contrast-enhanced MR
images were obtained every one to three months. If meta-
chronous distant metastases were identified, they were
managed, in principle, with repeat SRS. When miliary me-
tastases (numerous tiny enhanced lesions) and/or lepto-
meningeal carcinomatosis was newly documented, WBRT
was then indicated. Local control failure was defined as an
at least 20% increase in the diameter of the targeted lesions,
taking as a reference the pre-SRS diameter, irrespective of
whether the lesion was a true recurrence or delayed radi-
ation injury. Delayed radiation injury was differentiated
from tumor recurrence using the T1/T2 mismatch method
[20] and, in selected cases, 11C-methionine positron emis-
sion tomography. Additional SRS was possible provided
that the volume of the local tumor recurrence was small
enough for single-dose SRS. Surgical removal was indicated
when neurological signs became refractory to conservative
management, with a radiological diagnosis of local tumor
progression or radiation necrosis. Any adverse events at-
tributable to SRS procedures were evaluated based on the
National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI-CTCAE; ver.3.0). Before closing
the research database for analysis, the authors updated the
follow-up data of patients who had not visited our out-
patient department for more than two months. Inquiries
about the date and mode of death were made by directly
corresponding with the referring physician and/or the fam-
ily of the deceased patient. Neurological death was definedFigure 1 Contrast-enhanced T1-weighted MR images from 5 patients
obtained at the time of the initial SRS and the latest follow-up, respectively
post-treatment (lower): (A). A 60-year-old man with a tumor 14.3 mL in vol
with a tumor 15.2 mL in volume (upper), 8 months post-treatment (lower):
14 months post-treatment (lower): (D). An 80-year-old woman with a tumoas death attributable to central nervous system (CNS) me-
tastases including tumor recurrence and carcinomatous
meningitis. Events such as pneumonia due to a decline sec-
ondary to CNS disease progression were also scored as
neurological deaths.Statistical analysis
The overall survival (OS) rate was calculated by the
Kaplan-Meier product limit method. The neurological and
non-neurological death rates were calculated employing
Gray’s test [21], where each event was regarded as a com-
peting risk for another event. For the estimation of local
control failure rates and distant BM recurrence, Gray’s test
was similarly used, with subsequent WBRT and the pa-
tient’s death being regarded as competing events, respect-
ively. All of the above analyses were based on the interval
from the date of initial SRS treatment until the date of each
event. Univariate and multivariate analyses were performed
using the log-rank test and the Cox proportional hazards
model to investigate prognostic factors for OS. Possible
prognostic factors were selected with reference to other
SRS series [12-16]. The survival results were tested and
compared employing three prognostic scoring systems vali-
dated for SCLC: Diagnosis-specific graded prognosis assess-
ment (DS-GPA) [22], Radiation therapy oncology group
(RTOG)-recursive partitioning analysis (RPA) [23] and
Rades’s survival score [24]. The statistical processing soft-
ware package “R” version 3.0.1 (The R Foundation for Stat-
istical Computing, Vienna, Austria) was used for all
statistical analyses. A P-value of < 0.05 was considered to
indicate a statistically significant difference.treated with 2-session SRS. The upper and lower images were
. A 71-year-old man with a tumor 19.2 mL in volume (upper), 3 months
ume (upper), 11 months post-treatment (lower): (B). A 64-year-old man
(C). A 61-year-old man with a tumor 17.0 mL in volume (upper),
r 22.3 mL in volume (upper), 9 months post-treatment (lower): (E).
Figure 2 Overall treatment results of patients with BM from
SCLC treated with SRS. OS after initial SRS: (A) The MST was
8.1 months (95% CI: 6.2-15.6). Cumulative incidence of cause-specific
mortality: (B) The solid and dotted lines represent neurological and
non-neurological death rates, respectively.
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Twenty-five patients (61%) had active systemic disease
and/or extra-CNS metastases and 32 (78%) received sys-
temic chemotherapy following the initial SRS. In total,
121 tumors were treated at the time of the initial SRS.
The median planning target volume (PTV) was 0.6 mL
(range: 0.1-19.1 mL). The median number of BM at
diagnosis was 2 (range: 1–10 tumors) and the median
cumulative PTV was 3.8 mL (range: 0.6-28.2 mL). Pre-
scribed doses ranged from 10 Gy to 22 Gy (median:
20 Gy). Five patients with large tumors were allocated to
2-session SRS (Figure 1).
Full clinical results were available for all 41 patients as
none were lost to follow-up. The median follow-up time
after SRS was 8.1 months (range: 0.8-37.8). At the time
of assessment, 5 patients (12%) were alive and 36 (88%)
had died. The causes of death were intracranial local
progression in 3 cases, meningeal carcinomatosis in 3
and progression of the primary lesion in 30. The actuar-
ial 1- and 2-year OS rates after SRS were 44% and 17%,
respectively (Figure 2a). The median survival time
(MST) was 8.1 months (95% confidence interval (CI):
6.2-15.6). Cumulative incidences of 1- and 2-year neuro-
logical death after SRS adjusted for competing events
(non-neurological death) were 5% and 13%, respectively
(Figure 2b). The results of analyses for variables possibly
correlating with OS are shown in Table 2. In univariate
analysis, high KPS (P < 0.001), controlled extra-CNS dis-
ease (P = 0.005), post-SRS chemotherapy (P = 0.009) and
having a single BM (P = 0.011) influenced OS rates sig-
nificantly. The proportional hazards model for OS iden-
tified high KPS (HR: 0.308, 95% CI: 0.128-0.742, P =
0.009) and post-SRS chemotherapy (HR: 0.324, 95% CI:
0.130-0.809, P = 0.016) as the only two prognostic factors
independently predicting OS rates.
The survival results were tested with validated prognostic
scoring systems (Table 3, Figure 3). The DS-GPA showed
significant differences in MST when patients were dichoto-
mized prior to comparison, due to the small number of pa-
tients included: DS-GPA 1.5 ≤: 10.3 months (95% CI: 5.2-
24.3), DS-GPA 0–1.0: 7.2 months (95% CI: 4.6-13.3), (P =
0.022, log-rank test) (Figure 3a). MSTs by RTOG-RPA class
were: class I: 9.2 months (95% CI: 2.8-NA), class II:
8.3 months (95% CI: 6.2-18.5), class III: 6.7 months (95%
CI: 0.8-15.6). The MST decreased by class, but the differ-
ence was not statistically significant (P = 0.188, log-rank
test). A survival scoring system specifically for patients with
BM from SCLC, as proposed by Rades et al. [24], allowed
stratification by 6-month patient survival rates: 15 points:
80% (95% CI: 41–95), 9–12 points: 73% (95% CI: 49–87),
5–8 points: 44% (95% CI: 14–72) (P = 0.034, log-rank test)
(Figure 3b).
Only the 95/121 tumors (79%) in 34 patients (83%) who
had sufficient radiological follow-up data were analyzedherein because the other 7 patients died from extra-CNS
progression without follow-up MR imaging. Six metastases
(6%) were eventually diagnosed as local recurrence or de-
layed radiation injury at a median time of 10.8 months after
SRS (range: 6.9-17.0 months). The 6-month and 1-year ac-
tuarial rates of local tumor control failure were 0% and
14%, respectively (Figure 4a). Two-session SRS conducted
in five patients achieved a durable tumor volume reduction
coupled with symptom relief in all cases with sufficient
radiological follow-up (Figure 1), though one of these pa-
tients experienced local tumor recurrence in the brainstem
which eventually resulted in neurological death (Figure 1c).
Table 2 Statistical analysis of factors predicting patient survival after SRS
Parameter
(No. of patients)
OS (months) Univariate* Multivariate**
Median (95% CI) P Value P Value HR (95% CI)
Age 0.205 0.456 0.758 (0.363-1.58)
65 years or less (17) 12.6 (6.2-20.5)
More than 65 years (24) 6.7 (4.4-13.3)
KPS < 0.001 0.009 0.308 (0.128-0.742)
90 or more (23) 13.3 (6.7-24.2)
Less than 90 (18) 5.4 (4.3-12.2)
Extra-CNS disease status 0.005 0.450 0.674 (0.242 − 1.88)
None or inactive (16) 18.0 (6.7-29.9)
Active (25) 6.7 (4.7-12.6)
Post-SRS chemotherapy 0.009 0.016 0.324 (0.130-0.809)
Yes (32) 12.4 (6.7-18.0)
No (9) 5.2 (0.8-8.3)
Total PTV at initial SRS 0.063 0.672 0.842 (0.381-1.86)
5 mL or less (21) 7.8 (6.2-24.2)
More than 5 mL (20) 8.2 (2.8-15.6)
No. of BM 0.011 0.161 0.551 (0.240-1.27)
Single (18) 16.8 (5.2-29.9)
Multiple (23) 6.7 (4.7-12.2)
SRS: stereotactic radiosurgery, OS: overall survival, CI: confidence interval, KPS: Karnofsky performance status, CNS: central nervous system, PTV: planning target
volume, BM brain metastases.
*Log-rank test.
**Cox proportional hazards model.
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recurrence at a median time of 6.4 months after SRS
(range: 3.1-15.2 months). The actuarial 6- and 12-month
distant BM recurrence rates were 22% and 44%, respect-
ively (Figure 4b).
Eighteen patients (44%) required repeat SRS for remote
or local BM recurrence. The total number of SRS sessions
ranged up to 5 (median: 1) and the total number of BM
treated per patient up to 28 (median: 3). Seven patients
(17%) had to undergo salvage WBRT at a median time of
10.8 months after SRS (range: 6.1-22.6 months) necessi-
tated by the subsequent development of miliary BM and/or
leptomeningeal dissemination. Microsurgical resection was
necessary for local tumor recurrence in one patient at
15 months after SRS.
None of the adverse effects observed in this series
exceeded NCI-CTCAE grade 3 toxicity. Two patients de-
veloped delayed radiation injury (NCI-CTCAE grade 3),
which significantly impacted their quality of life due to
neurological deficits. Both required prolonged use of ste-
roids coupled with hyperbaric oxygen therapy and eventu-
ally showed clinical and radiological stabilization.
Discussion
BM continues to be a significant threat to quality of life
in patients with lung cancer. The risk of developing BMin SCLC is higher than with other histologies. Seute
et al. reported the cumulative risk of BM at 2 years after
the diagnosis to be 49% to 65% in SCLC [25]. Because of
this high likelihood of BM from SCLC, PCI has long
been advocated to reduce or delay BM development
[3,4,6]. For newly diagnosed BM from SCLC, WBRT has
been shown to provide a moderate extension of life and
amelioration of neurological symptoms [22,26,27]. How-
ever, survival remains poor in patients with BM, prob-
ably because the presence of BM is associated with
systemic disease relapse [28].
Out of concern over the potential neurotoxicity associ-
ated with WBRT [5,11] seen in long-term survivors, and
in the hope that local control and survival can be further
improved over the results achieved with WBRT, SRS has
recently been used as an alternative in selected patients
with a limited number of BM and primary histologies
other than SCLC. The delivery of highly focused radi-
ation with a sharp dose fall-off is theoretically expected
to reduce delayed neurotoxicity. Despite increasing
interest in the use of SRS, a strategy that attempts to
omit the use of WBRT in the management of BM from
SCLC must be adapted with great caution. The argu-
ment that the pathology of SCLC is unsuitable for SRS,
because of the disseminated nature of this malignancy,
cannot be ignored.





Sperduto et al. 2010 [22]
(299)
Videtic et al. 2007 [23]
(154)
Rades et al. 2013 [24]
(86)
Initial treatment
SRS 100% 4% 1% 0%
WBRT 0% 83% 84% 100%
Patients with 1–3 BM 68% 61% NA 28%
Overall MST in months 8.1 4.9 4.9 NA
DS-GPA (MST in months)
0-1.0 7.2 (20) 2.8
1.5-2.5 8.1 (15) 5.3
3.0 24.3 (5) 9.6
3.5-4.0 10.3 (1) 17.1
RTOG-RPA (MST in months)
Class III 6.7 (6) 2.5
Class II 8.3 (25) 5.3
Class I 9.2 (10) 8.6
Rades’ score (6-months survival rate)
5-8 44% (9) 3%
9-12 73% (22) 41%
15 80% (10) 89%
BM brain metastases, SCLC small cell lung cancer, SRS stereotactic radiosurgery, WBRT whole brain radiotherapy, NA not available, MST median survival time,
DS-GPA diagnosis specific-graded prognosis assessment, RTOG-RPA radiation treatment oncology group recursive partitioning analysis.
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more than eight months? The DS-GPA index validated
by Sperduto et al. is one of the most reliable and widely
used diagnostic tools for predicting the survival of pa-
tients with newly diagnosed BM [22]. The DS-GPA did,
in fact, predict survival with statistical significance in the
present study as well. In the original DS-GPA study,
where the majority of patients (82.6%) received WBRT
as the sole treatment, the survival of patients with newly
diagnosed BM from SCLC was 4.90 months, which was
obviously worse than those for patients with tumors at
other primary sites. If confined to DS-GPA scores no
more than 1.0, the MST was as short as 2.79 months.
Considering that almost half the patients had DS-GPA
scores of 1 or less in our cohort, the survival outcomes
after SRS appear to be acceptable. When it comes to the
RTOG-RPA, only 51 patients (4%) in the original RTOG
database had SCLC histology [23]. Videtic et al. validated
the RTOG-RPA classes for the prognostic stratification
of BM even in the setting of SCLC in their retrospective
analysis of 154 patients [27]. In their experience, 130 pa-
tients (84%) underwent WBRT alone and the MST was
4.9 months, which coincidentally was equivalent to that
of the DS-GPA. Historical comparison showed the MST
in our cohort (8.1 months) to be similar to that of
RTOG-RPA class I (8.6 months). More recently, Rades
et al. proposed a new survival scoring system specificallyfor patients with BM from SCLC, wherein therapeutic
WBRT alone was employed and 6-month survival rates
were compared. KPS, number of BM, and extracranial
metastasis were associated with survival and were thus
included in the score. This scoring system predicted the
survival rates in our cohort as well, with the rates in the
present study apparently being higher in the lower score
classes.
The lack of effective therapies for achieving long-term
control of extracranial disease makes the interpretation
of intervention studies in BM from SCLC difficult [1].
The results of applying local therapy to the brain are
likely to be confounded by the competing high risk of
death from extracranial disease. Thus, in the present
study, we also conducted a competing risk analysis for
appropriate evaluation of the efficacy of such a local
treatment and the results suggested that continuing ac-
tive radiosurgical management might reduce neuro-
logical death rates. Although it is impossible to compare
the rate of neurological death because previous studies,
unfortunately, did not provide information about the
mode of death, our experience suggests that reducing
the neurological death rate by adequately controlling
BM might contribute to prolonging OS.
With regard to prognostic factors, high KPS and post-
SRS chemotherapy were associated with improved pa-
tient survival in both uni- and multivariate analyses.
Figure 3 Survival results stratified with prognostic scoring
systems. Diagnosis-specific graded prognostic assessment (DS-GPA):
(A). Rades’s survival score: (B).
Figure 4 Cumulative incidence of local and distant brain failure.
The 6- and 12-month local tumor control failure rates were 0% and 14%,
respectively: (A). The 6- and 12-month distant intracranial recurrence
rates were 22% and 44%, respectively: (B).
Yomo and Hayashi Radiation Oncology 2014, 9:152 Page 7 of 9
http://www.ro-journal.com/content/9/1/152These results are consistent with those of previous stud-
ies focusing mainly on salvage treatment. Identifying
prognostic factors for longer survival in patients with
BM would be critically important for assigning patients
to the optimal treatment modality. This observation sug-
gests that selected subsets of patients can be expected to
experience prolonged survival, although the expected
survival of patients with BM from SCLC may be limited
in the majority of cases.Some of our patients experienced metachronous re-
currence outside the treated area after the initial SRS. In
fact, subsequent SRS was needed in nearly half of our
patients (18; 44%), mostly because of remote BM recur-
rence. These patients were successfully managed with
minimal toxicity by virtue of early detection of local or
remote recurrence. As to making this treatment strategy
feasible, meticulous clinical and radiographic post-SRS
follow-up is required to monitor for recurrent disease. Only
seven of our patients (17%) eventually required salvage
WBRT because of miliary metastases or leptomeningeal
dissemination, neither of which is treatable with SRS. We
strategically withhold WBRT until it is presumably the
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living longer than ever and may thus be at risk for late
manifestation of leptomeningeal carcinomatosis. This strat-
egy may, however, also be fraught with the hazards of de-
layed intervention. We must establish a more efficient
framework for appropriately assigning patients to either
WBRT or SRS, to achieve longer survival as well as less
treatment-related toxicity.
The patient inclusion criteria, in terms of the number
of BM, are more aggressive than those employed in
previous studies because our treatment protocol, in
principle, referred to that of the JLGK 0901 study pro-
spectively investigating the results of gamma knife SRS
for up to ten BM without upfront WBRT. The criticism
that such an upfront SRS strategy has not yet been vali-
dated for BM from SCLC and its safety is still of major
concern must be acknowledged. Adverse events ob-
served in the present series were rare and toxic severity
was NCI-CTCAE grade 3 at a maximum, which we con-
sider to be acceptable given the difficult clinical situa-
tions. However, the evidence of clinical safety and
efficacy remains insufficient and awaits validation in fu-
ture studies.
The present results must be interpreted with great
caution. Although the treatment results after upfront
SRS suggested survival similar to that obtained with
therapeutic WBRT in properly stratified populations, a
patient selection bias inherent to the retrospective ap-
proach is unavoidable. One of the critical issues in the
present study is that the reason for PCI having been
omitted could not be specified for all cases. In addition,
the present study included more patients with smaller
numbers of BM (≤3), as compared to the past studies
cited (Table 3). It should be appreciated that the current
study cannot address the potential role of SRS in com-
parison to WBRT because this was not a randomized
but rather a small retrospective observational study. The
survival advantage in previous randomized trials sup-
porting PCI as the standard of care also cannot be ig-
nored. However, recent refinements of the SRS
apparatus and imaging techniques as well as advance-
ments in systemic therapy and patient care have the po-
tential to influence the modern management of BM
from SCLC. Whether an upfront SRS strategy omitting
WBRT is a rational alternative to conventional radiation
therapy in patients with BM from SCLC can be eluci-
dated only by a prospective randomized study. We con-
sider the present retrospective study to have been
necessary as a means of hypothesis generation for future
investigation of such issues. Another criticism, that the
study time frame is more recent than those of the previ-
ous studies and would thus tend to have better results,
can also be raised. However, over the last two decades,
the survival of patients with SCLC has improved verylittle (0.63 days per year), despite numerous attempts to
identify more efficacious treatments [29]. When it comes
to SCLC patients with BM, OS has remained around
5 months since a multi-institutional European phase II
study reported that the MST in SCLC BM patients, with
no signs of extracranial tumor involvement, was
4.7 months in 1998 [26]. Another weakness of this study
is that the relatively small sample size may have resulted
in the dataset being underpowered to assess hypotheses
and potential prognostic factors. We plan to accumulate
further experience with this treatment strategy, in hopes
of drawing more robust conclusions. An additional
weakness of this study is that only 83% of patients had
radiological follow-up, which could lead to overesti-
mation of the true local and remote BM control rates.
Conclusion
The OS in patients with no more than 10 BM from
SCLC was slightly more than eight months after upfront
SRS. Patient survival could be predicted by the DS-GPA
and Rades’s prognostic grading systems. The current
study results suggest upfront SRS to be a potentially ef-
fective and minimally invasive treatment option for se-
lected patients with limited numbers of BM from SCLC.
Although SRS provided durable local tumor control, re-
peat salvage treatment was needed in nearly half of our
patients to achieve control of distant BM.
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